Clinical evidence of hematopoietic restoration with placental/umbilical cord blood (PCB) grafts indicates that PCB can be a useful source of hematopoietic stem cells for routine bone marrow reconstitution. In the unrelated setting, human leukocyte antigen (HLA)-matched donors must be obtained for candidate patients and, hence, large panels of frozen HLA-typed PCB units must be established. 
The large volume of unprocessed units, consisting mostly of red blood cells, plasma, and cryopreservation medium, poses a serious difficulty in this effort because storage space in liquid nitrogen is limited and costly. We report here that almost all the hematopoietic colony-forming cells present in PCB units can be recovered in a uniform volume of 20 ml by using rouleaux formation induced by hydroxyethyl starch and centrifugation to reduce the bulk of erythrocytes and plasma and, thus, concentrate leukocytes. This method multiplies the number of units that can be stored in the same freezer space as much as 10-fold depending on the format of the storage system. We have also investigated the proportion of functional stem/progenitor cells initially present that are actually available to the recipient when thawed cryopreserved PCB units are infused. Progenitor cell viability is measurably decreased when thawed cells, still suspended in hypertonic cryopreservative solutions, are rapidly mixed with large volumes of isotonic solutions or plasma. The osmotic damage inflicted by the severe solute concentration gradient, however, can be averted by a simple 2-fold dilution after thawing, providing almost total recovery of viable hematopoietic progenitor cells.
It is now known that the concentrations of hematopoietic progenitor cells in placental/umbilical cord blood (PCB) collections are similar (1) (2) (3) to those in collections of bone marrow for transplantation. The long-term hematopoietic reconstitution of a Fanconi anemia patient with PCB from an unaffected sibling demonstrated that PCB collections contain sufficient stem cells for allogeneic bone marrow restoration (4) . Since the initial case, several dozen patients with genetic diseases and hematological malignancies (5) have been transplanted with allogeneic PCB from siblings, both human leukocyte antigen (HLA) identical and partially mismatched (6) (7) (8) , and from HLA-matched, unrelated donors (8) . A remarkable attribute of these transplants has been their relative freedom from graft-versus-host disease (J. Kurtzberg (12) (13) (14) , but their procedures required transferring the blood from collection bags to other vessels, thereby exposing the blood to the risk of bacterial and fungal contamination and increasing the possibility of identification errors. These manipulations are also time and labor intensive and do not fit easily in the routine demanded by medium-and large-scale' PCB processing and storage.
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The second problem is that hematopoietic stem and progenitor cells can be affected by cryopreservation and thawing as usually performed, which reduces significantly the number of viable cells available for transplant. Considering this problem, Buckner et al. (15) observe that " . . . data suggest the feasibility of cryopreserving allogeneic marrow with the caveat that relatively large cell doses should be collected to compensate for the inevitable cell loss from marrow processing, cryopreservation and thawing." The methods described below overcome these obstacles.
MATERIALS AND METHODS
PCB Collection from the Delivered Placenta. Blood remaining in the delivered placenta and umbilical cord was retrieved by using protocols approved by the Institutional Review Boards of the New York Blood Center and Mount Sinai School of Medicine. The procedure, described previously (10), consists of inserting the 16-gauge needle of a standard 450-ml blood donor set containing CPD A anticoagulant (citrate/ phosphate/dextrose/adenine) (Baxter Health Care, Deerfield, IL) into the umbilical vein of the delivered placenta and letting PCB drain by gravity into the blood bag. To facilitate collection and reduce the likelihood of contamination with maternal blood and secretions, the placenta is placed in a plastic-lined, absorbent cotton pad suspended from a specially constructed support frame. The 63 ml of CPD A used in the standard blood transfusion bag, calculated for 450 ml of blood, is reduced to 23 ml by draining 40 ml into a graduated cylinder just prior to collection. This volume of anticoagulant matches better the PCB volumes usually retrieved (<170 ml). Moreover, since CPD A is isotonic and has neutral pH, the ratio of anticoagulant to blood is not critical, as in the case of ACD (acid/citrate/dextrose).
Reduction of PCB Bulk: Preparation of Leukocyte Concentrates (LCs). After removal of aliquots for routine testing, 6%
(wt/vol) hydroxyethyl starch (HES) (Hespan; DuPont) is added to the anticoagulated PCB to a final concentration of 1.2%-i.e., in a 1:5 volume ratio-to enhance its low red blood cell sedimentation rate (< 1 mm/h without HES). A leukocyterich supernatant is then separated by centrifuging the PCB/ HES mixture in the original collection blood bag (50 x g for 5 min at 10°C). The leukocyte-rich supernatant is expressed from the bag into a 150-ml Plasma Transfer bag (Baxter Health Care) and centrifuged (400 x g for 10 min) to (wt/vol) DMS0 added from either 20% or 50% (wt/vol) solutions (Fresh) and after they were thawed. Data are presented as the mean total cell counts ± SEM for the complete volume of the LC unit. teen PCB units were thawed and two aliquots were taken immediately from each. One of these aliquots was processed and tested without removing DMSO ("unwashed" aliquot), while the other was processed to eliminate DMSO ("washed") immediately after thawing. Samples from each aliquot were mixed with ethidium bromide (for viability testing) or with culture medium (for progenitor cell assays) as soon as the DMSO was removed from the "washed" aliquot (within 15 min of thawing). The results are summarized in Table 3 .
In each case, the new procedure resulted in increased leukocyte viability, as determined by both direct cell counts and formation of hematopoietic cell colonies. (11) . In our experiments, loss of viability was minimized by adding one volume of isotonic diluent with osmolarity "310 mosmol/liter to the cell suspension in 10% DMSO, which suggests that hyperosmolarity (17) (10% DMSO 1.25 M) and osmotic shock upon a brusque reduction of osmolality may be responsible. Similar observations were reported in 1978 by Goldman et al. (18) , who showed that clonogenic activity declined rapidly in thawed bone marrow and peripheral blood cells suspended in 10% DMSO and that this decline could be largely prevented by a prompt 1:2 dilution in saline. These authors credited E. D. Thomas (Fred Hutchinson Cancer Research Center, Seattle) with suggesting the 1:2 postthaw dilution as a means of reducing granulocyte aggregation.
Dilution of the freshly thawed cryopreserved unit with an equal volume of isotonic solution also allows the sample to be thawed and prepared for infusion in the laboratory under controlled conditions rather than at the bedside. Removal of the cryoprotective medium can be performed there, without harm to the units: clonogenic activity and viability remain essentially unchanged, even if removal of diluted DMSO is delayed for several hours. Furthermore, removing DMSO eliminates its deleterious effects on the transplant recipient (19, 20) .
Conceivably, the same procedure could be applied to cryopreserved bone marrow and peripheral blood stem and progenitor cells to improve viability and allow more time between thawing a unit and infusing it. During that time, there might be an opportunity, for example, to purge or remove contaminating malignant cells or to introduce chemical or genetic labels into cells before infusion.
These improvements make frozen PCB a more effective source of stem cells for unrelated marrow reconstitution in the treatment of inherited disease and hematologic malignancy and, potentially, for recombinant DNA-based gene therapy.
